Ron Bose
Impact in
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 43
- HER2/EGFR in Cancer Research 37
-
- Cancer Genomics and Diagnostics 16
- Breast Cancer Treatment Studies 7
- Co-authors
- Richard Kolesnick (5 shared papers)Marcel Verheij (2 shared papers)Adriana Haimovitz‐Friedman (2 shared papers)Kathleen W. Scotto (1 shared paper)Zvi Fuks (1 shared paper)Leonard Ira Zon (1 shared paper)Éva Szabó (1 shared paper)Michael J. Birrer (1 shared paper)
- Journals
- Clinical Cancer Research (7 papers)Breast Cancer Research and Treatment (6 papers)Journal of Clinical Oncology (5 papers)Annals of Oncology (4 papers)Journal of Biological Chemistry (4 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Ron Bose
84 papers receiving 14.9k citations
Ron Bose's Hit Papers
Peers
Comparison fields: 5 of 144
- Cancer Research 4.0k
- Oncology 5.6k
- Pulmonary and Respiratory Medicine 3.4k
- Molecular Biology 7.1k
- Pathology and Forensic Medicine 1.1k
Countries citing papers authored by Ron Bose
This map shows the geographic impact of Ron Bose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Bose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Bose more than expected).
Fields of papers citing papers by Ron Bose
This network shows the impact of papers produced by Ron Bose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Bose. The network helps show where Ron Bose may publish in the future.
Co-authors
The 25 scholars most cited alongside Ron Bose, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Comprehensive genomic characterization of squamous cell lung cancers Hit paper breakdown → | 2012 | 3290 |
| 2 | Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis Hit paper breakdown → | 1996 | 1664 |
| 3 | Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers Hit paper breakdown → | 2012 | 988 |
| 4 | Whole-genome analysis informs breast cancer response to aromatase inhibition Hit paper breakdown → | 2012 | 840 |
| 5 | Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals Hit paper breakdown → | 1995 | 778 |
| 6 | Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer Hit paper breakdown → | 2012 | 705 |
| 7 | Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts Hit paper breakdown → | 2013 | 527 |
| 8 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 9 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study Hit paper breakdown → | 2019 | 445 |
| 10 | CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer Hit paper breakdown → | 2017 | 441 |
| 11 | DGIdb: mining the druggable genome Hit paper breakdown → | 2013 | 414 |
| 12 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study Hit paper breakdown → | 2018 | 413 |
| 13 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study Hit paper breakdown → | 2021 | 310 |
| 14 | 2007 | 292 | |
| 15 | 2016 | 257 | |
| 16 | 2015 | 251 | |
| 17 | 2016 | 247 | |
| 18 | 2006 | 183 | |
| 19 | 2017 | 165 | |
| 20 | 2008 | 154 |
About Ron Bose
Ron Bose is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 88 papers that have together received 15.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (37 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Cancer Genomics and Diagnostics (16 papers), Breast Cancer Treatment Studies (7 papers), Advanced Breast Cancer Therapies (6 papers), Glycosylation and Glycoproteins Research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Sphingolipid Metabolism and Signaling (5 papers). The work is most often cited by research in Cancer Research (4.0k citations), Oncology (5.6k citations), Pulmonary and Respiratory Medicine (3.4k citations), Molecular Biology (7.1k citations) and Pathology and Forensic Medicine (1.1k citations). Ron Bose has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Richard Kolesnick, Marcel Verheij, Adriana Haimovitz‐Friedman, Kathleen W. Scotto, Zvi Fuks, Leonard Ira Zon, Zvi Fuks, Éva Szabó, Michael J. Birrer and Xin Lin. Their work appears in journals such as Clinical Cancer Research, Breast Cancer Research and Treatment, Journal of Clinical Oncology, Annals of Oncology and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.